Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > CTKB Cytek Biosciences > Key Indicators
CTKB Cytek Biosciences
13.105
-1.195-8.36%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
2.19% 288.515 -6.91% 266.8414 -4.64% 245.5932 10.15% 250.6957
Receivable Turnover(T)
10.13% 4.4754 6.25% 4.8814 -7.17% 6.0996 0.64% 5.4738
Inventory Turnover(T)
-5.00% 1.5442 6.01% 1.6345 6.60% 1.6793 -10.87% 1.7687
Fixed Assets Turnover(T)
-52.75% 11.3497 -57.87% 11.9415 -69.62% 12.1602 -45.14% 32.0235
Total Asset Rate(T)
23.09% 0.3242 -14.33% 0.4107 -11.59% 0.3907 -41.44% 0.3745
ROIC
-103.11% -0.138% -- -0.736% -- -0.417% -- 0.635%
ROE
-105.59% -0.233% -- -1.310% -- -1.031% -- 0.000%
ROA
-105.42% -0.200% -109.16% -0.724% -106.27% -0.569% -- 0.000%
FCF to Sales
-- -- -- -- -- -- -98.58% 0.208%
FCF to Net Income
-- -- -- -- -- -- -87.36% 8.864%
Efficiency Ratios
Profitability Ratios TTM
Gross Margin
-1.64% 61.604% -3.82% 60.374% 4.82% 61.146% 11.05% 61.855%
Operating Margin
-102.81% -0.369% -96.32% 0.651% -73.88% 4.085% -51.36% 7.157%
Net Margin
-104.40% -0.616% -110.69% -1.764% -107.09% -1.457% -- 0.000%
EBITDA Margin
-78.19% 0.0288% -85.68% 0.0261% -69.97% 0.0503% -57.87% 0.0697%
R & D Expense Ratio
14.52% 20.820% 15.53% 19.940% 24.01% 19.730% 29.49% 19.100%
Sales Expense Ratio
20.03% 21.030% 23.23% 20.370% 24.39% 19.740% 19.64% 19.310%
Administration Expense Rate
45.76% 20.130% 71.92% 19.410% 61.23% 17.590% 61.35% 16.280%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-- 3.440% -- 2.996% -- 3.115% -- --
Total Assets to Common Equity
6.32% 119.894% -- 119.899% -- 119.311% -- 114.384%
Debt to Asset Ratio
-- 3.779% -- 3.612% -- 3.658% -- --
Current Ratio
-27.00% 10.6969 35.89% 10.4668 34.01% 10.2589 65.50% 13.0115
Quick Ratio
-32.29% 9.1948 38.91% 9.14 39.00% 9.2168 71.98% 11.8818
GrowthRatios
Growth Ratios
FCF 1 Year Growth
-- -- -- -- -- -- -- -98.045%
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Cytek Biosciences, Inc. is a life sciences technology company engaged in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in December 2014 and is headquartered in Fremont, CA.
CEO: Dr. Wenbin Jiang, PhD
Market: NASDAQ
Listing Date: 07/23/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist